Objective
Gene transfer into the haematopoietic system is a promising therapy for several inherited (immunodeficiency’s, liposome storage disorders, haemophilias) or acquired human diseases (AIDS, cancer). Yet the genetic modification of human haematopoietic stem cells (HSC) to provide a lifelong supply of corrected progeny remains the most daunting challenge to the success of this endeavour, because HSC are mostly quiescent and hence difficult to transduce. A major breakthrough has been obtained through the creation of lentiviral vectors, which can mediate the efficient integration and long-term expression of transgenes into no dividing cells, including HSC. This project aims at exploiting the tremendous potential of lentiviral vectors for gene transfer into HSC, in order to bring this new technology from bench to bedside for the therapy of human disease, and to exact its value for the competitiveness of the EU biomedical industry.
Fields of science
Call for proposal
Data not availableFunding Scheme
CSC - Cost-sharing contracts
Coordinator
10124 Torino (Turin)
Italy
See on map
Participants (5)
20132 Milano
See on map
91002 Evry
See on map
69364 Lyon
See on map
Milano
See on map
1211 Geneve
See on map